Pneumococcal conjugate vaccines − cost effectiveness in Turkey

Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news

Related Links:

Publication date: July 2019Source: American Journal of Kidney Diseases, Volume 74, Issue 1Author(s): Michael Z. David
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Nosocomial infections have become alarming with the increase of multidrug resistant bacterial strains of Acinetobacter baumannii. Being the causative agent in approximately 80% of the cases, these pathogenic gram-negative species could be deadly for hospitalized patients, especially in intensive care units utilizing ventilators, urinary catheters and nasogastric tubes. Primarily infecting an immuno-compromised system, they are resistant to most antibiotics and are the root cause of various types of opportunistic infections including but not limited to septicemia, endocarditis, meningitis, pneumonia, skin and wound sepsis a...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
ConclusionsWhile the rate of pneumococcal carriage and acquisition did not differ between CLH and HUC, HIV affected families had exposure to a wider range of serotypes including non-vaccine type serotypes and antibiotic resistant serotypes, than HIV unaffected families.
Source: Indian Journal of Pediatrics - Category: Pediatrics Source Type: research
Administration of pneumococcal conjugate vaccine (PCV) in early infancy substantially reduces the risk of pneumococcal acute otitis media (AOM), according to a new Cochrane review.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pediatrics News Source Type: news
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
Conditions:   Melanoma;   Hodgkin Lymphoma;   Non Small Cell Lung Cancer Intervention:   Sponsor:   University of Cologne Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) resulted in sharply reduced pneumonia cases in Kenya, according to areport from an international team of researchers.
Source: JAMA - Category: General Medicine Source Type: research
Conclusions: Further, adequately powered, high quality studies are needed. It is crucial for individual institutions to monitor their own vaccination rates to determine if there is scope for performance improvement. PMID: 31208087 [PubMed - in process]
Source: Medicina (Kaunas) - Category: Universities & Medical Training Authors: Tags: Medicina (Kaunas) Source Type: research
(Wellcome Trust Sanger Institute) Researchers have mapped the most common bacterial cause of pneumonia around the world and revealed how these bacteria evolve in response to vaccination. Scientists from the Wellcome Sanger Institute and their collaborators carried out a global genomic survey of Streptococcus pneumoniae, discovering 621 strains across more than fifty countries. Published in The Lancet Infectious Diseases, the study will help predict which strains will be important for new pneumococcal vaccines.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Pneumococcal infections are major causes of morbidity and mortality worldwide. We use routine hospital admissions data and time-series modelling analysis to estimate the impact of the seven and thirteen valent...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research article Source Type: research
More News: Drugs & Pharmacology | Meningitis Vaccine | Middle East Health | Pneomococcal Vaccine | Turkey Health | Vaccines